Klin Onkol 1996; 9(3): 98-102.
Summary: Cisplatin comprises the basic component of chemofherapeutic regimens used in oncogynecology. In the dose 75-90 mg/m2 it belongs to the group with profound emetic effect. Introducing 5-HT3 receptors blockings agents in clinical practice improved the tolerance of the severe emetic effect of anticancer drugs. In our study prospective comparison of two antiemetic regimens, used in our oncogynecologic unit, was performed. The first regimen included dexamethason 16 mg and ondansetron (Zofran) 3x8 mg on the 1. day of chemotherapy, 2. day dexamethason 4x1 g and ondansetron 3x4 mg. 25 women in 137 courses of cisplatin (75-90 mg/m2) based combination chemotherapy were evaluated. The second regimen consisted of Kytril-granisetron 3 mg i. v. in bolus on the 1. day and after 24 hours 3 mg i. v. with the same application of dexamethason as in the first group. 25 women with 138 cisplatin based courses (75-90 mg/m2) were evaluated. Both regimens were tolerated well. The difference in effectiveness occurs in the first 24 hours after application of cisplatin (acute phase) and granisetron proved higher antiemetic effect. In the group with granisetron 100% tolerance and very good tolerance was archieved in 9% of patient frequently than in the first regimen and unsatisfactory tolerance and failure was lower in 11 % of women compared to the first group. Comparable results of both groups concerning late vomiting and nause were observed.
